Immupharma reports success of partner's latest Lupus drug trial

Drug development firm ImmuPharma said Monday that its key scientific collaboration partner and the inventor of ImmuPharma's lead compound, Lupuzor, has confirmed the effectiveness of a product known as Lupuzor peptide P140.

Drug development firm ImmuPharma said Monday that its key scientific collaboration partner and the inventor of ImmuPharma's lead compound, Lupuzor, has confirmed the effectiveness of a product known as Lupuzor peptide P140.

Partner CNRS released a statement saying that in a clinical trial involving 149 patients suffering with the Lupus, an autoimmune disease, the peptide was well tolerated by patients and led to a regression of the disease.

It said: "Under the CNRS patent, ImmuPharma-France, which funded the trial, has an exclusive licence to use the peptide. Now the final phase of clinical tests should soon confirm these results and contribute to the development of a drug without the side effects of existing treatments, which use cortico-steroids and immuno-suppressants."

The share price rose 9.73% to 62p by 13:40.

NR

Recommended

Share tips of the week – 15 October
Share tips

Share tips of the week – 15 October

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
15 Oct 2021
Trading: stash the family cash in this cheap wealth management firm
Trading

Trading: stash the family cash in this cheap wealth management firm

Wealth management is a growth market. Rathbone Brothers should be a prime beneficiary – and looks cheap. Matthew Partridge explains the best way to pl…
12 Oct 2021
What the best-performing investment trusts of the past 20 years can teach us
Investment trusts

What the best-performing investment trusts of the past 20 years can teach us

Forty-two trusts have risen more than tenfold over the last two decades. What made the winners stand out? And how can we identify future outperformers…
12 Oct 2021
Activision Blizzard: a cheap play on videogames
Share tips

Activision Blizzard: a cheap play on videogames

Videogame maker Activision Blizzard has been in the news for the wrong reasons lately. But it has a bright future, says Stephen Connolly.
11 Oct 2021

Most Popular

Why the world’s most important economic data release has unnerved markets
US Economy

Why the world’s most important economic data release has unnerved markets

The US added only 194,000 jobs in September, far shorter than the 500,000 that were expected. John Stepek explains why markets didn't react as they no…
11 Oct 2021
How to invest in SMRs – the future of green energy
Energy

How to invest in SMRs – the future of green energy

The UK’s electricity supply needs to be more robust for days when the wind doesn’t blow. We need nuclear power, says Dominic Frisby. And the future of…
6 Oct 2021
Inflation is still one of the biggest threats to your personal finances
Investment strategy

Inflation is still one of the biggest threats to your personal finances

Central bankers and economists insist inflation will be gone by next year. We're not so sure, says Merryn Somerset Webb. So if you haven’t started to …
1 Oct 2021